Catalyst Pharmaceuticals Inc logo

Catalyst Pharmaceuticals Inc share price today

(CPRX)

Catalyst Pharmaceuticals Inc share price is $22.02 & ₹1,863.84 as on 7 Dec 2024, 2.30 'hrs' IST

$22.02

0.32

(1.47%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Catalyst Pharmaceuticals Inc share price in Dollar and Rupees. Guide to invest in Catalyst Pharmaceuticals Inc from India. Also see the sentimental analysis on Indian investors investing in Catalyst Pharmaceuticals Inc. Get details on the Indian mutual funds that are investing in Catalyst Pharmaceuticals Inc. Get Analyst recommendations and forecasts along with all the Catalyst Pharmaceuticals Inc's financials.

Catalyst Pharmaceuticals Inc share price movements

  • $21.79
    $22.08

    Day's Volatility :1.31%

  • $13.00
    $24.27

    52 Weeks Volatility :46.44%

Catalyst Pharmaceuticals Inc Returns

PeriodCatalyst Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
10.43%
-5.7%
0.0%
6 Months
38.84%
-0.8%
0.0%
1 Year
53.36%
9.9%
0.0%
3 Years
214.04%
10.7%
-19.7%

Catalyst Pharmaceuticals Inc Key Statistics

in dollars & INR

Previous Close
$21.7
Open
$21.83
Today's High
$22.08
Today's Low
$21.79
Market Capitalization
$2.6B
Today's Volume
$664.7K
52 Week High
$24.27
52 Week Low
$13.0
Revenue TTM
$460.5M
EBITDA
$211.4M
Earnings Per Share (EPS)
$1.18
PE Ratio
18.39
Profit Margin
31.01%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
28.29%

How to invest in Catalyst Pharmaceuticals Inc from India?

It is very easy for Indian residents to invest directly in Catalyst Pharmaceuticals Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Catalyst Pharmaceuticals Inc stock in both rupees (INR) and dollars (USD). Search for Catalyst Pharmaceuticals Inc or CPRX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Catalyst Pharmaceuticals Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Catalyst Pharmaceuticals Inc shares which would translate to 0.038 fractional shares of Catalyst Pharmaceuticals Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Catalyst Pharmaceuticals Inc

88%

Period: Sep 7, 2024 to Dec 6, 2024. Change in 30 Days versus previous period

Search volume for Catalyst Pharmaceuticals Inc on INDmoney from India has grown in the last 30 days as on Dec 7, 2024. 88% more investors are searching Catalyst Pharmaceuticals Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Catalyst Pharmaceuticals Inc

  • BlackRock Inc

    15.67%

  • Vanguard Group Inc

    6.74%

  • Deerfield Management Co

    5.22%

  • State Street Corp

    4.77%

  • Dimensional Fund Advisors, Inc.

    2.53%

  • Pacer Advisors, INC.

    2.35%

Analyst Recommendation on Catalyst Pharmaceuticals Inc

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 13 Wall street analysts offering stock ratings for Catalyst Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
10
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Catalyst Pharmaceuticals Inc

What analysts predicted

Upside of 46.46%

Current:

$22.02

Target:

$32.25

Insights on Catalyst Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 98.50M → 128.69M (in $), with an average increase of 12.2% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 23.27M → 43.88M (in $), with an average increase of 25.0% per quarter

Catalyst Pharmaceuticals Inc Technicals Summary

Sell

Neutral

Buy

Catalyst Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

Catalyst Pharmaceuticals Inc Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Catalyst Pharmaceuticals Inc
-4.45%
38.84%
53.36%
214.04%
382.22%
Regeneron Pharmaceuticals, Inc.
-5.97%
-23.34%
-8.6%
17.41%
110.02%
Biontech Se
11.44%
21.29%
14.9%
-59.29%
309.79%
Alnylam Pharmaceuticals, Inc.
-7.77%
64.08%
48.09%
42.33%
108.61%
Vertex Pharmaceuticals Incorporated
-6.83%
-4.83%
31.35%
122.6%
109.65%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Catalyst Pharmaceuticals Inc
18.39
18.39
0.0
2.04
0.28
0.18
NA
5.54
Regeneron Pharmaceuticals, Inc.
18.56
18.56
1.12
44.92
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.06
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Catalyst Pharmaceuticals Inc
Buy
$2.6B
382.22%
18.39
31.01%
Regeneron Pharmaceuticals, Inc.
Buy
$82.9B
110.02%
18.56
33.61%
Biontech Se
Buy
$28.5B
309.79%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$32.7B
108.61%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$118.4B
109.65%
32.84
-4.51%

About Catalyst Pharmaceuticals Inc

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Organization
Catalyst Pharmaceuticals Inc
Employees
167
CEO
Mr. Richard John Daly M.B.A.
Industry
Health Technology

Management People of Catalyst Pharmaceuticals Inc

NameTitle
Mr. Richard John Daly M.B.A.
President, CEO & Director
Dr. Steven R. Miller Ph.D.
Executive VP, COO & Chief Scientific Officer
Dr. Gary Ingenito M.D., Ph.D.
Chief Medical & Regulatory Officer
Mr. Jeffrey Del Carmen
Executive VP & Chief Commercial Officer
Mr. Michael W. Kalb CPA
Executive VP, Treasurer & CFO
Ms. Mary Coleman
VP & Head of Investor Relations
Mr. Brian Elsbernd J.D.
Chief Compliance Officer & Chief Legal Officer
Mr. Pete Curry Sr.
Vice President of Sales
Dr. Stanley Iyadurai M.D., Ph.D.
Senior Vice President of Medical Affairs & Drug Discovery
Dr. Preethi Sundaram Ph.D.
Chief Strategy Officer

Important FAQs about investing in Catalyst Pharmaceuticals Inc from India :

What is Catalyst Pharmaceuticals Inc share price today?

Catalyst Pharmaceuticals Inc (CPRX) share price today is $22.02.

Can Indians buy Catalyst Pharmaceuticals Inc shares?

Yes, Indians can invest in the Catalyst Pharmaceuticals Inc (CPRX) from India.

With INDmoney, you can buy Catalyst Pharmaceuticals Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Catalyst Pharmaceuticals Inc at zero transaction cost.

How can I buy Catalyst Pharmaceuticals Inc shares from India?

It is very easy to buy Catalyst Pharmaceuticals Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Catalyst Pharmaceuticals Inc be purchased?

Yes, you can buy fractional shares of Catalyst Pharmaceuticals Inc with INDmoney app.

What are the documents required to start investing in Catalyst Pharmaceuticals Inc stocks?

To start investing in Catalyst Pharmaceuticals Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Catalyst Pharmaceuticals Inc

Today’s highest price of Catalyst Pharmaceuticals Inc (CPRX) is $22.08.

Today’s lowest price of Catalyst Pharmaceuticals Inc (CPRX) is $21.79.

What is today's market capitalisation of Catalyst Pharmaceuticals Inc

Today's market capitalisation of Catalyst Pharmaceuticals Inc CPRX is 2.6B

What is the 52 Week High and Low Range of Catalyst Pharmaceuticals Inc

  • 52 Week High

    $24.27

  • 52 Week Low

    $13.00

How much percentage Catalyst Pharmaceuticals Inc is down from its 52 Week High?

Catalyst Pharmaceuticals Inc (CPRX) share price is $22.02. It is down by 99% from its 52 Week High price of $24.27.

How much percentage Catalyst Pharmaceuticals Inc is up from its 52 Week low?

Catalyst Pharmaceuticals Inc (CPRX) share price is $22.02. It is up by 1% from its 52 Week Low price of $13.00.

What are the historical returns of Catalyst Pharmaceuticals Inc?

  • 1 Month Returns

    -4.45%

  • 3 Months Returns

    38.84%

  • 1 Year Returns

    53.36%

  • 5 Years Returns

    382.22%

Who is the Chief Executive Officer (CEO) of Catalyst Pharmaceuticals Inc

Mr. Richard John Daly M.B.A. is the current Chief Executive Officer (CEO) of Catalyst Pharmaceuticals Inc.